Last Updated 22 April 2015
Gram-negative infections (GNIs) comprise a large portion of hospital-treated infections (HTIs), which represent a high-value segment of the antibacterial market given the severity of these infections. In the past developers have focused heavily on anti-gram-positive therapies, like those against MRSA, which has allowed the number of antibiotics for GNIs in late-stage pipeline to dwindle. Therefore, the GNI market provides wide market opportunity for developers that can tackle segments of unmet need. In particular, rising multidrug resistance (MDR) in key gram-negative pathogens (GNPs) (e.g., Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae) leave physicians with limited therapeutic options. With fewer alternatives, high volume use of a few current agents creates selective pressure for the further development of drug-resistance to therapy. Therefore, opportunity awaits developers who can provide therapies that not only overcome drug-resistance to current therapies, but are safe and tolerable and can stave off emergence of antibiotic-resistance by using novel mechanisms of action.